How Psilocybin Changes Your Personality: The Openness Effect

The Enduring Impact of Psilocybin on Personality

Personality traits are generally considered stable in adulthood, particularly after the age of 30 [MacLean et al., 2011]. However, research into psychedelic compounds, especially psilocybin, challenges this long-held belief. A groundbreaking 2011 study by Johns Hopkins researchers, led by Roland R. Griffiths, demonstrated that a single high-dose psilocybin session could induce significant and lasting changes in a core personality dimension known as 'openness to experience' [Griffiths et al., 2011]. These changes were not transient; they were observed to persist for at least 14 months, with some participants experiencing effects for even longer. The magnitude of these changes was remarkable, surpassing the typical shifts seen over decades of adult development, during which openness often tends to decline [Griffiths et al., 2011].

What is 'Openness to Experience'?

Openness to experience is one of the five major domains of personality in the widely accepted Five-Factor Model (FFM). It encompasses traits such as curiosity, imagination, creativity, aesthetic sensitivity, intellectual engagement, and a willingness to embrace new ideas and values [Costa & McCrae, 1992]. Individuals high in openness tend to be more creative, empathetic, and psychologically flexible. The Johns Hopkins study found that the increase in openness was more significant than changes typically seen over decades of normal adult development, a period during which openness usually tends to decrease [Griffiths et al., 2011]. This trait is crucial for personal growth, learning, and adapting to new situations, making its enhancement a significant finding in psychedelic research.

Beyond Openness: Other Personality Changes

While 'openness to experience' is the most consistently reported personality change, other studies have also indicated broader effects of psilocybin on personality. A 2018 study on patients with treatment-resistant depression (TRD) found that psilocybin therapy led to significant decreases in neuroticism and increases in extraversion, alongside increases in openness [Erritzoe et al., 2018]. Neuroticism, characterized by anxiety, emotional instability, and negative affect, decreased significantly, moving participants towards a healthier personality profile. Extraversion, associated with sociability, assertiveness, and positive emotions, also saw notable increases. These findings suggest that psilocybin's influence extends beyond just openness, contributing to a more balanced and adaptive personality structure. Some research also points to trend-level increases in conscientiousness, a trait linked to self-discipline and achievement striving [Erritzoe et al., 2018]. These multidimensional changes highlight psilocybin's potential to foster holistic psychological well-being.

The Neurobiological Basis: Psilocybin and Neuroplasticity

The enduring personality changes observed after psilocybin administration are thought to be linked to its effects on neuroplasticity – the brain's ability to reorganize itself by forming new neural connections [Grieco et al., 2022]. Psilocybin primarily acts on serotonin 5-HT2A receptors, which are abundant in brain regions associated with mood, perception, and cognition. Activation of these receptors is believed to facilitate a state of increased neural plasticity, allowing for greater flexibility in thought patterns and behaviors [Carhart-Harris & Goodwin, 2017]. This enhanced neuroplasticity may explain how psilocybin can help individuals break free from rigid thought patterns often seen in conditions like depression and anxiety, fostering new perspectives and a greater capacity for personal growth. Research suggests that this neuroplastic effect can lead to long-lasting changes, far beyond the acute effects of the substance itself [Madsen et al., 2020].

How Psilocybin Enhances Brain Function

Beyond simply creating new connections, psilocybin's interaction with the brain is complex and multifaceted. It has been shown to transiently disrupt established neural networks, particularly the default mode network (DMN), which is often overactive in conditions like depression and anxiety [Carhart-Harris et al., 2012]. By temporarily reducing the dominance of the DMN, psilocybin allows for increased connectivity between brain regions that typically do not communicate as freely. This increased connectivity is associated with a broader range of cognitive and emotional experiences, contributing to the observed increases in openness and psychological flexibility [Carhart-Harris et al., 2012]. This temporary disruption and subsequent reorganization of brain networks can be likened to a “reset” for the brain, allowing for new perspectives and patterns of thought to emerge [Carhart-Harris & Friston, 2010].

The Role of Mystical Experiences

A significant factor in the lasting personality changes, particularly the increase in openness, appears to be the occurrence of a ‘mystical experience’ during the psilocybin session [Griffiths et al., 2011]. Roland Griffiths, a leading researcher at Johns Hopkins, defines a mystical experience as encompassing a sense of interconnectedness with all people and things, accompanied by feelings of sacredness and reverence. Participants in the 2011 study who reported such experiences showed the most significant and sustained increases in openness. This suggests that the profound subjective experience facilitated by psilocybin plays a crucial role in mediating its long-term psychological effects. The intensity of these mystical-type experiences has been consistently correlated with positive long-term outcomes in various psychedelic-assisted therapies [Johnson et al., 2014; Bogenschutz et al., 2015].

Therapeutic Implications and Future Directions

The ability of psilocybin to induce lasting personality changes, particularly increased openness and decreased neuroticism, holds significant therapeutic potential. These shifts are highly desirable in the context of mental health treatment, as they are associated with improved psychological well-being and resilience. For individuals struggling with conditions like depression and anxiety, fostering greater openness can lead to new coping mechanisms, enhanced emotional processing, and a more positive outlook on life [Erritzoe et al., 2018]. The reduction in neuroticism, a key vulnerability factor for affective disorders, further underscores psilocybin's potential to promote mental health [Weiss et al., 2024].

Psilocybin in Clinical Settings

Research is actively exploring psilocybin-assisted therapy for various mental health disorders, including treatment-resistant depression, PTSD, and addiction. Clinical trials have shown promising results, with psilocybin demonstrating rapid and sustained antidepressant effects [Carhart-Harris et al., 2016]. The insights gained from studies on personality changes provide a deeper understanding of how psilocybin works at a fundamental psychological level. For instance, the observed increase in openness could be a key mechanism through which psilocybin helps individuals process trauma or break free from addictive behaviors, by allowing them to consider new perspectives and embrace change. The lasting nature of these personality shifts suggests that psilocybin could offer more than just symptomatic relief, potentially leading to fundamental and enduring improvements in mental health.

The therapeutic paradigm often involves a carefully prepared environment and psychological support, emphasizing the importance of integration sessions to help individuals process their experiences and incorporate new insights into their daily lives [Johnson et al., 2008]. This holistic approach, combining pharmacological effects with psychological support, is believed to be crucial for maximizing the therapeutic benefits and fostering lasting personality changes.

Safety and Considerations

While the therapeutic potential of psilocybin is significant, it is crucial to emphasize that these studies are conducted under highly controlled and supervised clinical settings. The use of psilocybin outside of such environments carries inherent risks, including the potential for adverse psychological reactions such as anxiety, paranoia, or acute psychosis, particularly in individuals predisposed to psychiatric conditions [Griffiths et al., 2011]. Therefore, self-medication or recreational use is strongly discouraged. The legal status of psilocybin also varies widely, and its use is illegal in many jurisdictions.

For those interested in exploring the benefits of functional mushrooms for general well-being, brands like Secret Shrooomz offer a range of products designed to support cognitive function, mood, and overall vitality, without the psychoactive effects of psilocybin. These products leverage the natural properties of mushrooms like Lion's Mane, Reishi, and Cordyceps, which have been studied for their adaptogenic and health-promoting qualities. It's important to distinguish between functional mushrooms and psychedelic compounds, as their mechanisms of action and legal implications are entirely different.

As research progresses, the scientific community continues to unravel the complex mechanisms through which psilocybin influences personality and mental health. The ongoing studies aim to refine therapeutic protocols, identify optimal dosages, and determine the long-term efficacy and safety of psilocybin-assisted therapy. The ultimate goal is to harness the transformative potential of these compounds to address pressing mental health challenges and improve the quality of life for countless individuals.

Frequently Asked Questions (FAQ)

Q: How long do psilocybin-induced personality changes last?

A: Studies, such as the one conducted by Johns Hopkins, have shown that significant increases in openness to experience can last for at least 14 months after a single high-dose psilocybin session [Griffiths et al., 2011]. Some researchers believe these changes may be permanent, especially when associated with profound mystical experiences.

Q: Can psilocybin change other personality traits besides openness?

A: Yes, while openness is the most consistently reported change, research indicates that psilocybin can also lead to decreases in neuroticism and increases in extraversion. These changes generally move an individual towards a more adaptive and psychologically healthy personality profile [Erritzoe et al., 2018].

Q: Is it safe to use psilocybin for personality change?

A: The studies demonstrating these personality changes were conducted under highly controlled, clinically supervised conditions with psychologically healthy volunteers. The use of psilocybin outside of such settings carries risks, including potential for anxiety or fear responses. It is crucial to approach such substances with caution and under professional guidance [Griffiths et al., 2011].

Q: How does psilocybin cause these personality changes?

A: The changes are believed to be linked to psilocybin's ability to enhance neuroplasticity in the brain, particularly through its interaction with serotonin 5-HT2A receptors. This allows for the formation of new neural connections and a greater flexibility in thought patterns, which can lead to lasting psychological shifts [Grieco et al., 2022].

Q: Where can I find more information about psilocybin research?

A: For comprehensive and research-backed information, you can explore academic journals, university research hubs like Johns Hopkins, and reputable scientific publications. Websites such as secret.shrooomz.com/learn/microdosing-mushrooms-depression and secret.shrooomz.com/learn/psilocybin-ptsd-research also provide valuable resources on psilocybin and microdosing research.

References

• [Griffiths et al., 2011] Griffiths, R. R., Johnson, M. W., MacLean, K. A., Finan, A. A., & Jesse, R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1466–1480. https://gazette.jhu.edu/2011/10/31/one-dose-of-hallucinogen-may-create-lasting-personality-changes/
• [MacLean et al., 2011] MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1466-1480. https://pmc.ncbi.nlm.nih.gov/articles/PMC3537171/
• [Costa & McCrae, 1992] Costa, P. T., & McCrae, R. R. (1992). Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Psychological Assessment Resources.
• [Erritzoe et al., 2018] Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica, 138(5), 368–378. https://pmc.ncbi.nlm.nih.gov/articles/PMC6220878/
• [Grieco et al., 2022] Grieco, S. F., Mastrogiacomo, A. R., & Malenka, R. C. (2022). Psychedelics and Neural Plasticity: Therapeutic Implications. Biological Psychiatry, 92(10), 780-790. https://pmc.ncbi.nlm.nih.gov/articles/PMC9665925/
• [Carhart-Harris & Goodwin, 2017] Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology, 42(11), 2105–2113. https://pubmed.ncbi.nlm.nih.gov/28443617/
• [Madsen et al., 2020] Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Jørgensen, L. M., ... & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 30, 1-10. https://www.sciencedirect.com/science/article/pii/S0924977X20300602
• [Carhart-Harris et al., 2012] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Sandford, C., Nash, L., ... & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. https://www.pnas.org/content/109/6/2138
• [Carhart-Harris & Friston, 2010] Carhart-Harris, R. L., & Friston, K. J. (2010). The default-mode, ego-dissolution and the free-energy principle. Frontiers in Human Neuroscience, 8, 201. https://www.frontiersin.org/articles/10.3389/fnhum.2010.00201/full
• [Johnson et al., 2014] Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. https://pubmed.ncbi.nlm.nih.gov/25213996/
• [Bogenschutz et al., 2015] Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299. https://pubmed.ncbi.nlm.nih.gov/25586396/
• [Weiss et al., 2024] Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Carhart-Harris, R. L., & Kettner, H. (2024). Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological Medicine, 54(4), 757-766. https://www.cambridge.org/core/journals/psychological-medicine/article/personality-change-in-a-trial-of-psilocybin-therapy-v-escitalopram-treatment-for-depression/0E8A176E4CE91CC747A08E5E32EED738
• [Carhart-Harris et al., 2016] Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. https://pubmed.ncbi.nlm.nih.gov/27210031/
• [Johnson et al., 2008] Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620. https://pubmed.ncbi.nlm.nih.gov/18593734/